MEDI MIB BORTEZOMIB INJECTION

Get a Price/Quote

MEDI MIB BORTEZOMIB INJECTION Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Salt Composition
Bortezomib

Origin of Medicine
Indian

Dosage Form
Lyophilized powder for Injection

Pacakaging (Quantity Per Box)
1 vial per box

Drug Type
Allopathic

Ingredients
Bortezomib

Physical Form
Injection

Function
Treatment of multiple myeloma and mantle cell lymphoma

Recommended For
Anti-cancer treatment

Dosage
As directed by physician

Dosage Guidelines
Follow healthcare professionals instructions

Suitable For
Adults

Quantity
1 vial

Storage Instructions
Store below 30C, protect from light

Product Category
Oncology Injection

MRP
Available on request

Strength
2 mg per vial

Prescription Required
Yes

Reconstitution
Requires reconstitution before use

Shelf Life
24 months from manufacture

Side Effects
Nausea, fatigue, diarrhea, thrombocytopenia, neutropenia

Appearance
White to off-white lyophilized powder

Administration Route
Intravenous or subcutaneous

Packaging Type
Glass vial with carton

Marketed By
Medi Biotech Pvt. Ltd.

MEDI MIB BORTEZOMIB INJECTION Trade Information

Packaging Details
PACK OF 1 VIAL

Main Domestic Market
All India

About MEDI MIB BORTEZOMIB INJECTION

Medi Mib - Bortezomib 2 Mg

Specifications:-

Strength:2 mg
Composition:Bortezomib
Form:Injection
Manufacturer:biotech
Brand:Medi Mib
Packaging Size:pack of 1 vial

Note : MEDI MIB Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug..............

Targeted Treatment for Serious Cancers

MEDI MIB Bortezomib Injection offers targeted therapy for adults diagnosed with multiple myeloma or mantle cell lymphoma. This medicine leverages the benefits of bortezomib, a proven proteasome inhibitor, contributing to more precise treatment in oncology. The injection is formulated for maximum efficacy in anti-cancer protocols when administered under medical supervision.

Simple Reconstitution and Administration

This product is supplied as a lyophilized powder that requires reconstitution before use. Healthcare professionals prepare the injection by dissolving the powder as per provided guidelines, ensuring optimal safety and effectiveness. MEDI MIB Bortezomib Injection is then administered either intravenously or subcutaneously according to the prescribed dose schedule.

Quality Assured and Convenient Packaging

Each unit is supplied in a glass vial with a carton, ensuring integrity and protection from light. With a shelf life of up to 24 months and convenient storage conditions, MEDI MIB Bortezomib Injection meets the standards required for both healthcare providers and patients in an oncology setting.

FAQs of MEDI MIB BORTEZOMIB INJECTION:

Q: How is MEDI MIB Bortezomib Injection used for cancer treatment?

A: MEDI MIB Bortezomib Injection is primarily used to treat multiple myeloma and mantle cell lymphoma. It should be administered only under medical supervision, following the specific dosage and schedule advised by a healthcare professional.

Q: What is the process for preparing and administering this injection?

A: The injection is supplied as a lyophilized powder in a vial and requires reconstitution with a suitable solvent. A healthcare provider will prepare and administer the reconstituted solution either intravenously or subcutaneously as instructed by the prescribing physician.

Q: When should I expect to use this medication during my cancer treatment?

A: The usage schedule and dosage depend on your individual treatment plan. Your physician will determine the appropriate timing and frequency for administration, tailored to your specific medical condition and response to therapy.

Q: Where should I store MEDI MIB Bortezomib Injection?

A: Store the unopened vials below 30C, protected from direct light, and keep them out of reach of children. Always follow any additional storage instructions provided by your healthcare professional or pharmacist.

Q: What are the potential side effects of using this medicine?

A: Common side effects may include nausea, fatigue, diarrhea, thrombocytopenia (low platelet count), and neutropenia (low white blood cell count). If you experience severe or persistent symptoms, notify your doctor promptly.

Q: What benefits does this injection provide in oncology care?

A: Bortezomib, the active ingredient, targets specific pathways in cancer cells, helping to inhibit their growth. Its use can lead to improved management and control of multiple myeloma and mantle cell lymphoma under proper supervision.